AU3967297A - Use of gaba and nmda receptor ligands for the treatment of migraine headache - Google Patents

Use of gaba and nmda receptor ligands for the treatment of migraine headache

Info

Publication number
AU3967297A
AU3967297A AU39672/97A AU3967297A AU3967297A AU 3967297 A AU3967297 A AU 3967297A AU 39672/97 A AU39672/97 A AU 39672/97A AU 3967297 A AU3967297 A AU 3967297A AU 3967297 A AU3967297 A AU 3967297A
Authority
AU
Australia
Prior art keywords
gaba
treatment
nmda receptor
receptor ligands
migraine headache
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39672/97A
Inventor
Nancy C. Lan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cocensys Inc
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc filed Critical Cocensys Inc
Publication of AU3967297A publication Critical patent/AU3967297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
AU39672/97A 1996-08-01 1997-07-31 Use of gaba and nmda receptor ligands for the treatment of migraine headache Abandoned AU3967297A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2293796P 1996-08-01 1996-08-01
US60022937 1996-08-01
PCT/US1997/013430 WO1998005337A1 (en) 1996-08-01 1997-07-31 Use of gaba and nmda receptor ligands for the treatment of migraine headache

Publications (1)

Publication Number Publication Date
AU3967297A true AU3967297A (en) 1998-02-25

Family

ID=21812205

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39672/97A Abandoned AU3967297A (en) 1996-08-01 1997-07-31 Use of gaba and nmda receptor ligands for the treatment of migraine headache

Country Status (2)

Country Link
AU (1) AU3967297A (en)
WO (1) WO1998005337A1 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787530B1 (en) 1996-08-23 2004-09-07 Monash University Use of pregnane-diones as analgesic agents
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US20080255076A1 (en) * 2004-06-29 2008-10-16 Jadolabs Gmbh Steroid-Derived Pharmaceutical Compositions
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (en) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド Neurogenesis by angiotensin regulation
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ES2662500T3 (en) 2006-11-21 2018-04-06 Asarina Pharma Ab The use of pregnan and androstane steroids for the preparation of a pharmaceutical composition for the treatment of central nervous system disorders
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
DK2142514T3 (en) 2007-04-18 2015-03-23 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (en) 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
GB0711948D0 (en) * 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
GB2460350B (en) * 2008-04-25 2011-04-06 Kythera Biopharmaceuticals Inc Intermediates for the preparation of bile acids
CN101585862B (en) * 2008-05-20 2014-12-17 梅克芳股份公司 Novel steroids
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (en) 2010-03-03 2016-11-16 プロビオドルグ エージー Inhibitors of glutaminyl cyclase
BR112012022478B1 (en) 2010-03-10 2021-09-21 Probiodrug Ag HETEROCYCLIC GLUTAMINYL CYCLASE INHIBITORS (QC, EC 2.3.2.5), THEIR PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
MX2013001704A (en) 2010-08-12 2013-06-28 Kythera Biopharmaceuticals Inc Synthetic bile acid compositions and methods.
WO2012050907A2 (en) 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
FR2973031B1 (en) * 2011-03-23 2013-11-29 Univ Strasbourg DERIVATIVES OF ALLOPREGNANOLONE AND EPIALLOPREGNANOLONE AND USES THEREOF FOR TREATING A NEUROPATHOLOGICAL CONDITION
JP2014521662A (en) * 2011-07-29 2014-08-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Novel 17β-heteroaryl substituted steroids as modulators of GABAA receptors
RU2665571C2 (en) * 2011-09-08 2018-08-31 Сейдж Терапьютикс, Инк. Neuroactive steroids, compositions and uses thereof
CN104136452A (en) * 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
MX2014008895A (en) 2012-01-23 2014-11-25 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders.
DK2968369T3 (en) 2013-03-13 2018-12-17 Sage Therapeutics Inc NEUROACTIVE STEROIDS AND PROCEDURES FOR USE THEREOF
WO2014151411A1 (en) * 2013-03-15 2014-09-25 Brigham Young University Methods for treating inflammation, autoimmune disorders and pain
CN117304245A (en) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 19-nor steroids that stimulate neural activity and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
MX362543B (en) * 2013-04-17 2019-01-24 Sage Therapeutics Inc 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof.
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
SI3021852T1 (en) * 2013-07-19 2021-07-30 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HUE052308T2 (en) * 2013-08-23 2021-04-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
US11690855B2 (en) 2013-10-17 2023-07-04 Brigham Young University Methods for treating lung infections and inflammation
US20150203527A1 (en) 2014-01-23 2015-07-23 Brigham Young University Cationic steroidal antimicrobials
WO2015180679A1 (en) * 2014-05-29 2015-12-03 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CZ2014575A3 (en) * 2014-08-26 2016-02-24 Ústav organické chemie a biochemie AV ČR, v.v.i. Amphiphilic compounds exhibiting neuroprotecting activity
ES2808855T3 (en) * 2014-10-16 2021-03-02 Sage Therapeutics Inc Compositions and methods for treating CNS disorders
TW202235090A (en) * 2014-10-16 2022-09-16 美商賽吉醫療公司 Compositions and methods for treating cns disorders
PL3224269T3 (en) * 2014-11-27 2020-08-24 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3250210B1 (en) * 2015-01-26 2020-12-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CA2991313C (en) 2015-07-06 2023-12-19 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MA43815A (en) 2016-03-08 2021-04-07 Sage Therapeutics Inc NEUROACTIVE STEROIDS, COMPOSITIONS, AND THEIR USES
US10226550B2 (en) 2016-03-11 2019-03-12 Brigham Young University Cationic steroidal antimicrobial compositions for the treatment of dermal tissue
MA44526A (en) 2016-04-01 2021-06-02 Sage Therapeutics Inc OXYSTEROLS AND THEIR METHODS OF USE
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
DK3481845T3 (en) * 2016-07-11 2023-11-27 Sage Therapeutics Inc C17, C20 AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
ES2935057T3 (en) 2016-09-30 2023-03-01 Sage Therapeutics Inc C7 substituted oxysterols and these compounds for use as NMDA modulators
KR20230142639A (en) 2016-10-18 2023-10-11 세이지 테라퓨틱스, 인크. Oxysterols and methods of use thereof
US10959433B2 (en) 2017-03-21 2021-03-30 Brigham Young University Use of cationic steroidal antimicrobials for sporicidal activity
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
MX2020006608A (en) * 2017-12-22 2020-11-06 Sage Therapeutics Inc Compositions and methods for treating cns disorders.
WO2019126741A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US11718642B2 (en) 2018-01-12 2023-08-08 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
MX2020008182A (en) * 2018-02-11 2020-09-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Steroid derivative regulators, method for preparing the same, and uses thereof.
EP3829590A4 (en) * 2018-08-02 2022-05-18 PureTech LYT, Inc. Lipid prodrugs of pregnane neurosteroids and uses thereof
CN111040015B (en) * 2018-10-15 2022-03-18 南京诺瑞特医药科技有限公司 19-nor-C21 substituted steroid derivatives
CN113227114A (en) * 2018-10-19 2021-08-06 萨奇治疗股份有限公司 9(11) -unsaturated neuroactive steroids and methods of use thereof
CN109503694A (en) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 A kind of novel GABAAReceptor modulators and application thereof
JP2022510683A (en) 2018-12-05 2022-01-27 セージ セラピューティクス， インコーポレイテッド Neurostimulatory steroids and how to use them
CN111410673A (en) * 2019-01-08 2020-07-14 成都康弘药业集团股份有限公司 Steroid compound, use and preparation method thereof
CN111410678B (en) * 2019-01-08 2023-02-28 成都康弘药业集团股份有限公司 Steroid compound, application and preparation method thereof
TW202043204A (en) * 2019-01-14 2020-12-01 中國大陸商北京軒義醫藥科技有限公司 Tetrazolone substituted steroids and use thereof
CA3138176A1 (en) * 2019-04-27 2020-11-05 Health Research, Inc. Coumarin-modified androgens for the treatment of prostate cancer
CR20210629A (en) * 2019-05-31 2022-03-22 Sage Therapeutics Inc Neuroactive steroids and compositions thereof
CN114729000A (en) * 2019-06-27 2022-07-08 萨奇治疗股份有限公司 Compounds for the treatment of CNS disorders
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
IL291818A (en) * 2019-10-02 2022-06-01 Praxis Prec Medicines Inc Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists
CN115551874A (en) * 2020-03-18 2022-12-30 萨奇治疗股份有限公司 Neuroactive steroids and methods of use thereof
AU2022331486A1 (en) * 2021-08-20 2024-03-07 Md Imdadul H. KHAN Allopregnanolone analogues for hiv viremia and neurotoxicity protection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches

Also Published As

Publication number Publication date
WO1998005337A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
AU3967297A (en) Use of gaba and nmda receptor ligands for the treatment of migraine headache
AU7264298A (en) Apparatus and method for the reduction of snoring
AU1274897A (en) Apparatus and methods for vibratory intraluminal therapy employing magentostrictive transducers
AU697510B1 (en) Method and apparatus for the dry grinding of solids
AU4838097A (en) Apparatus for the treatment of specimens
AU3793697A (en) Apparatus and methods for the disinfection of fluids
AU1125797A (en) Apparatus and methods for ultrasonically enhanced fluid delivery
AU5608196A (en) Method of and apparatus for controlled dispensing of two-part bonding, casting and similar fluids and the like
AU2607295A (en) Drum coating: apparatus and methods
AU3323195A (en) Method and apparatus for direct retinal projection
AU2675095A (en) Indol derivatives useful for the treatment of migraine, composition and utilization
EP0732351A3 (en) Process and apparatus for the preparation of polyamides
AU2734895A (en) Process for the preparation of 3-aryluracils
AU4694396A (en) Method and apparatus for aggregate treatment
HUP9802307A3 (en) Process for the hydrogenation of imines and for the preparation of chloro-acetanilide derivatives
AU694955B2 (en) Pyridazinone derivatives and processes for preparing the same
AU1997197A (en) Device for in-line surface-hardening of products
AU2821295A (en) Compositions and methods for the treatment of tumors
AU4902596A (en) Multi-function fluid treatment system and method for using the same
AU3227195A (en) Fluid treatment apparatus
AU2173597A (en) Process for the preparation of tenidap
ZA966383B (en) Iridium-diphosphine complexes and process for the hydrogenation of imines
AU4818897A (en) Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens and tumors
AU4272996A (en) Means for treatment of particle mass
AU1489999A (en) Apparatus and procedure for the coating of objects